150 related articles for article (PubMed ID: 16571112)
1. N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.
Borlak J; Reamon-Buettner SM
BMC Med Genet; 2006 Mar; 7():30. PubMed ID: 16571112
[TBL] [Abstract][Full Text] [Related]
2. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients.
Borlak J; Reamon-Buettner SM
BMC Med Genet; 2006 Jul; 7():58. PubMed ID: 16827944
[TBL] [Abstract][Full Text] [Related]
3. Association of slow acetylator genotype of N-acetyltransferase 2 with Parkinson's disease in south Indian population.
Pandi S; Chinniah R; Sevak V; Ravi PM; Vijayan M; Vellaiappan NA; Karuppiah B
Neurosci Lett; 2020 Sep; 735():135260. PubMed ID: 32682841
[TBL] [Abstract][Full Text] [Related]
4. Association of
Walia HK; Singh N; Sharma S
Pharmacogenomics; 2022 Jan; 23(2):97-118. PubMed ID: 34911343
[No Abstract] [Full Text] [Related]
5. N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia.
Kamel AM; Ebid GT; Moussa HS
Tumour Biol; 2015 Aug; 36(8):6341-8. PubMed ID: 25804798
[TBL] [Abstract][Full Text] [Related]
6. Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
Zahra MA; Kandeel M; Aldossary SA; Al-Taher A
Biomed Res Int; 2020; 2020():8765347. PubMed ID: 32626768
[TBL] [Abstract][Full Text] [Related]
7. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese.
Chan DK; Lam MK; Wong R; Hung WT; Wilcken DE
Neurology; 2003 Mar; 60(6):1002-5. PubMed ID: 12654968
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
9.
Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
[TBL] [Abstract][Full Text] [Related]
10. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease.
Bandmann O; Vaughan J; Holmans P; Marsden CD; Wood NW
Lancet; 1997 Oct; 350(9085):1136-9. PubMed ID: 9343502
[TBL] [Abstract][Full Text] [Related]
11. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
Djordjevic N; Carrillo JA; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E
J Clin Pharmacol; 2011 Jul; 51(7):994-1003. PubMed ID: 20801937
[TBL] [Abstract][Full Text] [Related]
12. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease.
Bandmann O; Vaughan JR; Holmans P; Marsden CD; Wood NW
Mov Disord; 2000 Jan; 15(1):30-5. PubMed ID: 10634239
[TBL] [Abstract][Full Text] [Related]
13. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.
Bakayev VV; Mohammadi F; Bahadori M; Sheikholslami M; Javeri A; Masjedi MR; Velayati AA
Eur J Clin Pharmacol; 2004 Sep; 60(7):467-71. PubMed ID: 15316701
[TBL] [Abstract][Full Text] [Related]
14. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
15. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Molina JA; Ortí-Pareja M; Vázquez A; Ramos F; Duarte J; Coria F; Ladero JM; Alvarez-Cermeño JC; Benítez J
Neurology; 1998 Dec; 51(6):1587-92. PubMed ID: 9855506
[TBL] [Abstract][Full Text] [Related]
16. Association of N-acetyl transferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson's disease among Indians.
Chaudhary S; Behari M; Dihana M; Swaminath PV; Govindappa ST; Jayaram S; Singh S; Muthane UB; Juyal RC; B K T
Pharmacogenet Genomics; 2005 Oct; 15(10):731-5. PubMed ID: 16141799
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis.
Woolhouse NM; Qureshi MM; Bastaki SM; Patel M; Abdulrazzaq Y; Bayoumi RA
Pharmacogenetics; 1997 Feb; 7(1):73-82. PubMed ID: 9110365
[TBL] [Abstract][Full Text] [Related]
18. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
19. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men.
Hamasaki T; Inatomi H; Katoh T; Aono H; Ikuyama T; Muratani T; Matsumoto T
Int J Urol; 2003 Mar; 10(3):167-73. PubMed ID: 12622714
[TBL] [Abstract][Full Text] [Related]
20. The role of NAT2 gene polymorphism in aetiology of the most frequent neurodegenerative diseases with dementia.
Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
Neurol Neurochir Pol; 2007; 41(5):388-94. PubMed ID: 18033638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
